USA flag logo/image

An Official Website of the United States Government

Multiplex Detection of Mutations in Leukemia Patients

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85482
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
CA130501
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AMBION DIAGNOSTICS, INC.
Asuragen, Inc. 2150 WOODWARD ST AUSTIN, TX -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: Multiplex Detection of Mutations in Leukemia Patients
Agency: HHS
Contract: 2R44CA130501-02
Award Amount: $1,192,156.00
 

Abstract:

DESCRIPTION (provided by applicant): The long-term objective of this project is to develop a comprehensive molecular diagnostic assay for the detection of clinically relevant genetic abnormalities in patients with acute myeloid leukemia (AML), chronic myel ogenous leukemia (CML), and myeloproliferative disorders (MPDs). An estimated 44,000 new leukemia cases were predicted for 2008, with more than 21,000 deaths. Leukemia and MPDs are a group of similar diseases of the immune system that have different sympto ms, treatment targets, and prognoses. Risk stratification for these diseases has shifted from morphology and cytogenetic analysis to molecular markers. The variation in clinical outcome based on disease subtype underscores the very real need to ascertain f or each individual patient the combined cytogenetic and mutational events that underlie the disease; thus, these markers are used as an aid in diagnosis. Furthermore, the products of these cytogenetic and mutational alterations are being exploited as molec ular targets for novel therapies. Thus, these treatments will require companion diagnostics for comprehensive detection of molecular signatures that are predictive of treatment outcome. During Phase I we established the feasibility of detecting a small set of mutations with clinical relevance to leukemias and MPDs by demonstrating specific detection of a small set of mutations using a multiplex bead array system. Furthermore, we demonstrated simultaneous detection of mutations and translocations in a single -tube assay format. This resulted in the launch of an RUO diagnostic kit for the detection of NPM1 mutations (Signature(R) NPM1 Mutations). The primary goal of this Phase II grant is to expand the assay into a comprehensive system for simultaneous detectio n of a suite of sequence-level mutations and cytogenetic abnormalities. In addition to expanding the availability of molecular assays for leukemia/MPD testing, our single-tube, bead array format will simplify adoption into diagnostic laboratories in a mann er that reduces overall assay time, operator hands-on time, and training time and provides a software interface that simplifies reporting and facilitates reimbursement. We will develop a set of synthetic controls as well as a software interface for test se lection and reporting and perform stability testing and other assay performance experiments. We will also work with clinical collaborators to evaluate the test in a diagnostic laboratory setting on clinical patient samples. PUBLIC HEALTH RELEVANCE: The goa l of this Phase II SBIR project is to develop a reliable and cost-effective diagnostic test kit for mutations found in leukemia patients. Detection of mutations using our test will allow physicians and patients to choose the most effective treatment for ea ch individual patient while improving efficiency and driving down costs in the molecular diagnostic laboratory.

Principal Investigator:

Fei Ye
5126815200
FYE@ASURAGEN.COM

Business Contact:

Bernard Andruss
bandruss@asuragen.com
Small Business Information at Submission:

AMBION DIAGNOSTICS, INC.
Asuragen, Inc. 2150 WOODWARD ST AUSTIN, TX 78744

EIN/Tax ID: 043832139
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No